Clinical trials: Rhesus Isoimmunization
Blood Transfusion, Rhesus Isoimmunisation Due to Anti-D
RhD+ Blood Transfusion to Asian-type DEL Recipients
Red blood cells (RBCs) from Asian-type DEL blood group express very weak RhD antigen and are falsely typed as RhD-negative blood group in routine RhD testing.
- Conditions
- Blood Transfusion, Rhesus Isoimmunisation Due to Anti-D, Blood Group Antigen Abnormality
- Trial name
- NCT03727230
- Testing
- Blood transfusion
- Where
- 10 sites in China
- Volunteers
- 54 people
- Sponsor
- Guangzhou Blood Center
Rhesus Isoimmunization
Delayed Cord Clamping in Rhesus Disease of the Newborn
The objective of this clinical trial is to investigate the effects of delayed cord clamping on hyperbilirubinemia, the need for phototherapy, neonatal intensive care (NICU) admission
- Trial name
- NCT04600674
- Testing
- Delayed cord clamping, Early cord clamping
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Benha University
Rh Isoimmunization
Doppler or Amniocentesis to Predict Fetal Anemia
In pregnancies complicated by Rhesus disease, the mother has developed antibodies which cross the placenta and can cause anemia and death of the fetus.
- Trial name
- NCT00295516
- Testing
- Fetal Middle Cerebral Artery Doppler measurement
- Where
- Canada
- Volunteers
- 157 people
- Sponsor
- University of Toronto
Hemolytic Disease of the Fetus and Newborn
A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
The purpose of this study is to evaluate the safety in mother and neonate/infant of M281 administered to pregnant women who are at high risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn (EOS-HDFN).
- Trial name
- NCT03842189
- Testing
- M281
- Where
- 19 sites in United States, Australia and 7 more
- Volunteers
- 25 people
- Sponsor
- Janssen Research & Development, LLC
Hemolytic Disease of the Newborn, Fetal Anemia
Neonatal Outcomes on Direct Fetal Intravenous Immunoglobulin During Intrauterine Transfusion for Rhesus Isoimmunization
The goal of this clinical trial is to learn if giving intravenous immunoglobulin directly to the fetus during intrauterine transfusion can improve newborn outcomes in pregnancies affected by rhesus isoimmunization.
- Conditions
- Hemolytic Disease of the Newborn, Fetal Anemia, Rhesus Isoimmunization, Erythroblastosis Fetalis Due to RH Antibodies
- Trial name
- NCT07885592
- Testing
- Intrauterine Transfusion, Intravenous immunoglobulin (IVIG)
- Where
- India
- Volunteers
- 30 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Erythroblastosis, Fetal, Erythroblastosis Fetalis, Rh Disease
EPO-4-Rhesus Study
Up to 80% of infants with hemolytic disease due to maternal alloimmunization, treated with IUT, require at least one top-up transfusion for late anemia during the first 3 months of life.
- Conditions
- Erythroblastosis, Fetal, Erythroblastosis Fetalis, Rh Disease, Erythroblastosis Fetalis Due to RH Antibodies, Erythroblastosis Fetalis Due to Isoimmunization
- Trial name
- EPO-4-Rhesus (NCT03104426)
- Testing
- Darbepoetin Alfa
- Where
- Netherlands
- Volunteers
- 42 people
- Sponsor
- Sanquin-LUMC J.J van Rood Center for Clinical Transfusion Research